SEARCH

SEARCH BY CITATION

References

  • 1
    Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 21404.
  • 2
    Bartnik M, Rydén L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 188090.
  • 3
    Hu DY, Pan CY, Yu JM et al. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J 2006; 27: 25739.
  • 4
    Tamita K, Katayama M, Takagi T et al. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J 2007; 71: 83441.
  • 5
    Bartnik M, Malmberg K, Norhammar A, Tenerz A, Öhrvik J, Ryden L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004; 25: 19907.
  • 6
    Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 77395.
  • 7
    Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 2001; 44: 92945.
  • 8
    Ferrannini E, Gastaldelli A, Iozzo P. Pathophysiology of prediabetes. Med Clin North Am 2011; 95: 32739, vii-viii.
  • 9
    DeFronzo RA, Abdul-Ghani MA. Preservation of beta-cell function: the key to diabetes prevention. The Journal of clinical endocrinology and metabolism 2011; 96: 235466.
  • 10
    U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 124958.
  • 11
    Wallander M, Bartnik M, Efendic S et al. Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia 2005; 48: 222935.
  • 12
    Bartnik M, Malmberg K, Hamsten A et al. Abnormal glucose tolerance–a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004; 256: 28897.
  • 13
    Zhao T, Parikh P, Bhashyam S et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006; 317: 110613.
  • 14
    Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125: 1737.
  • 15
    Timmers L, Henriques JP, de Kleijn DP et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009; 53: 50110.
  • 16
    Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010; 391: 14058.
  • 17
    Lonborg J, Vejlstrup N, Kelbaek H et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 14919.
  • 18
    Anagnostis P, Athyros VG, Adamidou F et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011; 13: 30212.
  • 19
    Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 22706.
  • 20
    Farilla L, Bulotta A, Hirshberg B et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 514958.
  • 21
    Mu J, Woods J, Zhou YP et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695704.
  • 22
    Han SJ, Choi SE, Kang Y et al. Effect of sitagliptin plus metformin on beta-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats. Diabetes Res Clin Pract 2011; 92: 21322.
  • 23
    Subbarayan S, Kipnes M. Sitagliptin: a review. Expert Opin Pharmacother 2011; 12: 161322.
  • 24
    JESC/ACC Committee. Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 150213.
  • 25
    Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Investig 1967; 46: 32335.
  • 26
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 4129.
  • 27
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 28
    Lenzen M, Rydén L, Öhrvik J et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J 2006; 27: 296974.
  • 29
    DECODE Study Group. Glucose tolerance and cardiovascular mortality comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397405.
  • 30
    Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47: 38594.
  • 31
    Rydén L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88136.
  • 32
    Kosiborod M, Inzucchi SE, Krumholz HM et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008; 117: 101827.
  • 33
    Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: 298304.
  • 34
    Williams-Herman D, Engel SS, Round E et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010; 10: 7.
  • 35
    Muscelli E, Casolaro A, Gastaldelli A et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. The Journal of clinical endocrinology and metabolism 2012; 97: 281826.